Amphastar Pharmaceuticals AMPH Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by Amphastar Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The official record: Amphastar Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Amphastar Pharmaceuticals's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Amphastar Pharmaceuticals's total current liabilities?
- Amphastar Pharmaceuticals (AMPH) reported total current liabilities of $164.48M in Q1 2026.
- How has Amphastar Pharmaceuticals's total current liabilities changed year-over-year?
- Amphastar Pharmaceuticals's total current liabilities decreased by 17.4% year-over-year, from $199.05M to $164.48M.
- What is the long-term trend for Amphastar Pharmaceuticals's total current liabilities?
- Over 5 years (2020 to 2025), Amphastar Pharmaceuticals's total current liabilities has grown at a 7.1% compound annual growth rate (CAGR), from $112.2M to $158.16M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.